Lysando

Executive Summary

Lysando is a Finnish biotechnology company founded in 2015 that develops microbiome-friendly proteins to combat bacterial threats, including resistant hospital germs. Its core technology targets harmful bacteria while preserving the beneficial microbiome, aiming to heal rather than just treat infections. The company's approach addresses the growing challenge of antimicrobial resistance by providing safe, targeted protein innovations. As a private company, Lysando has not disclosed financial details or commercial products, but its technology holds potential in the biologics space. The company is based in Helsinki and operates in the early-stage biotech landscape, with no publicly announced partnerships or pipeline milestones. To advance its platform, Lysando will likely need to secure funding, initiate clinical trials, or form strategic collaborations. The lack of public data limits visibility into its progress, but the concept of microbiome-friendly antimicrobials aligns with industry trends.

Upcoming Catalysts (preview)

• Q3 2026Announcement of Series A or B funding round40% success
• TBDInitiation of first-in-human clinical trial for lead candidate20% success
• Q4 2026Partnership or licensing deal with larger pharma or biotech30% success